Trastuzumab (TZB), an antibody directed against the HER2 receptor, is commonly used to treat HER2-overexpressing (HER2+) breast cancer (Swain, Shastry, and Hamilton, 2022). This evidence concerns the gene ERBB2 and breast carcinoma.